- Home
- TKLF vs PHGE Comparison
TKLF vs PHGE Comparison
Compare TKLF & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- PHGE
- Stock Information
- Founded
- TKLF 2006
- PHGE 2015
- Country
- TKLF Japan
- PHGE Israel
- Employees
- TKLF N/A
- PHGE N/A
- Industry
- TKLF Other Specialty Stores
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- PHGE Health Care
- Exchange
- TKLF Nasdaq
- PHGE Nasdaq
- Market Cap
- TKLF 15.7M
- PHGE 12.6M
- IPO Year
- TKLF 2022
- PHGE N/A
- Fundamental
- Price
- TKLF $3.70
- PHGE $0.49
- Analyst Decision
- TKLF
- PHGE Strong Buy
- Analyst Count
- TKLF 0
- PHGE 1
- Target Price
- TKLF N/A
- PHGE $15.00
- AVG Volume (30 Days)
- TKLF 9.5K
- PHGE 316.5K
- Earning Date
- TKLF 07-10-2025
- PHGE 11-13-2025
- Dividend Yield
- TKLF N/A
- PHGE N/A
- EPS Growth
- TKLF N/A
- PHGE N/A
- EPS
- TKLF 1.57
- PHGE N/A
- Revenue
- TKLF $210,119,238.00
- PHGE N/A
- Revenue This Year
- TKLF N/A
- PHGE N/A
- Revenue Next Year
- TKLF N/A
- PHGE N/A
- P/E Ratio
- TKLF $2.35
- PHGE N/A
- Revenue Growth
- TKLF 7.38
- PHGE N/A
- 52 Week Low
- TKLF $2.20
- PHGE $0.34
- 52 Week High
- TKLF $6.60
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- TKLF 52.45
- PHGE 46.84
- Support Level
- TKLF $3.29
- PHGE $0.46
- Resistance Level
- TKLF $3.77
- PHGE $0.51
- Average True Range (ATR)
- TKLF 0.17
- PHGE 0.03
- MACD
- TKLF 0.03
- PHGE -0.01
- Stochastic Oscillator
- TKLF 79.63
- PHGE 31.86
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).